As 2025 comes to an end, we're proud of the dedication & scientific rigor that drive our work forward. We gave back in our local communities & rang in the holiday season this month. We look forward to advancing our pipeline & making a meaningful impact on patients' lives in 2026.

We're excited to initiate our global registrational Phase 3 study of barzolvolimab in #ColdU & symptomatic dermographism, designed to establish the efficacy & safety of barzolvolimab in patients who remain symptomatic despite prior treatment. More: https://t.co/jfmYVak14B

Pumpkins, pies & plenty of Dunkin' - autumn is in full swing at Celldex. Recently, we voted on a delicious spiced maple miso caramel apple pie as our contest winner, celebrated Halloween with pumpkin carving & candy, & enjoyed a surprise morning sweet treat event. Check it out!🍁

We are thrilled to welcome Teri Lawver to our leadership team as SVP & CCO. With a notable record of success across global biopharma & medtech companies, Teri's experience will be invaluable as we prepare for the potential launch of barzolvolimab. More: https://t.co/GV4DG0Iwlb

We presented new Phase 2 data demonstrating sustained efficacy + a well tolerated safety profile over a 20 week treatment period for barzolvolimab in two of the most common forms of #CIndU, cold urticaria (ColdU) & symptomatic dermographism (SD).  https://t.co/FpH1GKsPlq  #ACAAI25

We're excited to announce positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets mast cell depletion via stem cell factor starvation and neutralization of the alarmin thymic stromal lymphopoietin (#TSLP). Details: https://t.co/VwIxxsWUm2

"I think even as a provider, there have been moments where I have not fully gauged how anxiety-provoking and emotionally challenging it can be to have chronic #urticaria." Clinicians answer the hard questions about working with an often misunderstood community below. #UDAY2025

In honor of #UDAY2025, we're elevating the voices of clinicians who face the challenges of #urticaria head-on alongside their patients. Listen below as Drs. Michael Cameron, Sarina Elmariah & Daniel Soteres share insight into the exasperating symptoms #CSU and #CIndU often cause.

People with chronic #urticaria live with relentless itching, swelling & sleepless nights, yet many don’t see the burden. #UDAY2025 is a chance to raise awareness & amplify community voices. The Celldex team stands with those living with #CSU & #CIndU. We see you. #urticariaday

We are pleased to share data demonstrating barzolvolimab profoundly improves #angioedema, the swelling of the deeper dermal layers of the skin and mucous membranes, at 52 weeks in the Phase 2 clinical trial in #CSU. Learn more below & here: https://t.co/osYt181e1w #EAACI2025

We were pleased to present new data at #EAACI2025 demonstrating profound, sustained complete response & improved quality of life at 76 weeks—7 months post-dosing with barzolvolimab in #CSU. Find details & listen to the playback of our recent webcast here. https://t.co/gJUbYWihh8

Thanks to the community engagement efforts of Celldex team member Jesse Hall, we recently welcomed @BristolCC biology students & their Dean of #STEM to our Fall River branch. We appreciate opportunities to introduce students to summer internships across departments at Celldex!

Last week, we enjoyed a paint night organized by our Fall River Wellness Committee. We were lucky to have a warm, sunny day and enjoyed designing flower pots out by the water. It was a perfect evening to welcome spring with our teammates!🎨

Our Fall River team was excited to welcome @stonehill_info chemistry students to our office to learn about careers in #biotech. Team members guided students through a “day in the life," explaining their roles, key responsibilities & exciting aspects of working in biotech. 🔬

We're excited to welcome Clinical Data Manager Meghan O'Neil to Celldex! From the lab bench to clinical trials coordination, Meghan adds valuable perspective to our team. Read more about her below.

We are pleased to present positive data on measurements of disease control & quality of life from the Phase 2 barzolvolimab studies in patients with chronic #urticaria at #AAAAI25. Find details on this milestone for Celldex & those living with CSU/CIndU: https://t.co/CCs2bAwx97

We're grateful for the chance to reflect, appreciate our teammates and give back to our communities this holiday season. We recently held holiday get-togethers and gift drives in our offices, which allowed us to donate a variety of items to help local families in need. ❄️

This weekend, we presented positive results from the Phase 2 clinical trial of barzolvolimab in 2 of the most common forms of chronic inducible #urticaria, cold urticaria and symptomatic dermographism, at #ACAAI24. More from CMO Diane Young below. Details: https://t.co/2GauLikpF9

It felt like the perfect fall weather at our annual fall cornhole tournament and BBQ at our Fall River office last week! To complement the chilly yet sunny day, we had warm apple cider and apple crumble along with our traditional BBQ lunch.🍁

It took 3+ years and multiple healthcare providers for Head of Medical Affairs Suki Bagal to receive her diagnosis of both #CSU and #ColdU. In part 2 of her story, Suki takes us through her journey to diagnosis & the impact working at Celldex has had on her life. #UDAY2024